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                                              ABSTRACT 
 
    EVALUATION OF NIFEDIPINE TOCOLYSIS IN PRETERM 
LABOUR 
 
 
AIM OF THE STUDY 
 
1. To evaluate the Tocolytic effects of Calcium channel blocker – 
NIFEDIPINE in preterm labour  
2. To study the maternal and fetal effects of NIFEDIPINE. 
3. To compare the efficacy of Nifedipine  with control group in 
delaying delivery  for 48 hours in  idiopathic  spontaneous preterm 
labour 
       
MATERIALS AND METHODS 
 
STUDY DESIGN 
It is prospective study conducted in Government RSRM Lying in Hospital, 
Stanley Medical College, Chennai , from September 2012 to September 2013 
The study population comprised of patients who attended the casuality or 
outpatient department. There were 100 patients in Nifedipine group and 2 
patients were lost to follow-up. There were 100 patients in Control group and 
3 patients were lost to follow up. Study group received Nifedipine and control 
group were observed with bed rest. Both groups received intra muscular 
corticosteroids.written informed consent obtained. 
 
 
 
DRUG PROTOCOL 
 
GROUP A 
 
Tab. Nifedipine 20 mg was given orally. If uterine contractions persisted after 
90 minutes another 10 mg dose given. If the dosage suppressed uterine activity 
then maintenance of 10 mg given 6th hourly for 3 days. Dosage is gradually 
tapered and stopped. 
 
GROUP B 
Patients observed with bed rest 
Both the groups given intramuscular corticosteroids 
 
Success and Failure 
There are several studies by various authors suggesting several factors for 
assessment of success of tocolysis.  
 
In our study, successful tocolysis was defined as the delay of delivery with 
suppression of contractions for more than 48 hours from initiation of therapy.  
 
Failure of therapy is said to occur, when patient delivered within 48 hours of 
initiation of therapy and tocolysis was stopped when cervical dilatation 
progressed to > 3 cm or when there was spontaneous rupture of membranes.  
 
Hence our study is  confined to idiopathic spontaneous preterm labour and 
comparing the efficacy of Nifedipine with that of control in delaying delivery 
for 48 hours and regarding the maternal  and fetal effects of Nifedipine. 
 SUMMARY 
The success of Nifedipine as indicated by prolongation of pregnancy 
beyond 48 hours was observed in 73.4% of cases compared with 57% in 
controls P value was significant (< 0.001).78.57% of patients required 30 
mg to suppress uterine contractions whereas 21.4% required 20 mg to 
stop contractions. The prolongation of pregnancy more than 48 hours was 
found to be more in 31 -34 weeks of gestational age in Nifedipine and 
control groups. About 56.1% of patients in Nifedipine group had side 
effects which were reversed on discontinuation Headache ,maternal 
tachycardia were  the common side effects. There was no maternal 
mortality. About 11.1% and 38.46% of neonatal complications occurred 
in Nifedipine success and failure groups respectively. About 34.37 % and 
21.5% of Neonatal complications occurred in control success and failure 
groups.  When compared with 56.2% in control success group. 8.3% in 
Nifedipine success group had birth weight > 2.5kg compared to                          
6.5%in  control success group P value 0.001 statistically significant. 
Incidence of Respiratory Distress syndrome is 2.7 % and 15.38% in 
Nifedipine success and Failure respectively compared to 12.5% and 
16.9% in control success and failure groups P value is Significant (0.042) 
          
CONCLUSION 
 
Labour inhibiting drugs may not treat the cause of preterm labour but they 
only treat the symptoms, that is contractions. 
  These agents make the uterus refractory to contractile stimuli for a 
short time so that the perinatal outcome is improved.  
Key words – nifedipine ,tocolysis, preterm labour  
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INTRODUCTION 
 
Preterm labour and delivery is one of the biggest challenges for obstetricians and 
any endeavour to reduce the prenatal mortality, calls for a successful effort to 
reduce the problems of preterm birth, for no single obstetrical misfortune is more 
wasteful as prematurity. 
Preterm delivery affects 11% in U.S or even greater in developing countries 
(23.3% in India) and it accounts for 40-75% of neonatal deaths. Incidence of 
preterm labour and delivery show increasing trends and could be due to assisted 
reproductive techniques, psychosocial stress or medically induced prematurity. 
Improvement in neonatal care has remarkably improved preterm survival. There is 
increased focus to early preterm births <32 weeks which account for 1-2% of all 
births; but contribute to 60% of perinatal mortality and nearly all neurological 
morbidity. 
Rush et   al reported that 75% of neonatal deaths occurred in infants with 
gestational age between 32 and 37 weeks accounting for majority of neonatal 
deaths  and nearly one half of all cases of congenital neurologic disability. 
The social and  emotional cost of penatal mortality and morbidity associated 
with preterm birth is immeasurable .Ideally preterm labour should be prevented 
.With improved neonatal services greater degrees of prematurity are still 
compatible with full and subsequently normal development. 
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Pharmacological methods of inhibition of preterm labour  remains the  most 
effective means to delay delivery and improve neonatal outcome till a more 
effective means of prevention is identified .In many instances, delaying delivery 
till the fetus is sufficiently mature is a tremendous gain for the fetus at no 
disadvantage to the mother. All that we have achieved so far is the possibility of 
gaining a few days with use of tocolytic agents. Our study is concerned with the 
Efficacy of Nifedipine – a calcium channel blocker as a tocolytic agent. 
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REVIEW OF LITERATURE 
 
DEFINITION 
Preterm labour is defined by the WHO as the onset of labour prior to the 
completion of 37 weeks of gestation in a pregnancy beyond 20 weeks of gestation. 
Preterm labour is defined as the onset of regular, painful, frequent, uterine 
contractions causing progressive effacement and dilatation of cervix occurring 
before 37 completed weeks from the first day of last menstrual period. 
(Anderson 1977) 
 
THRESHOLD OF VIABLITY 
Births before 26 weeks, especially those weighing less than 750 g are at the 
current threshold of viability and these preterm infants pose a variety of complex 
medical, social and ethical considerations (ACOG, 2002, 2008). 
According to current guidelines of American Academy of Pediatrics 
(Braner, coworkers 2008) it is considered appropriate not to initiate resuscitation 
for infants younger than 23 weeks or birth weight less than 400g these infants are 
described as fragile and vulnerable because of their immature  
organ systems (Vohr and Allen,2005). 
Overall 25 percent of infants born at 22 to 25 weeks had severe neurological 
disability and 72 percent exhibited learning disability. Active brain development 
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normally occurs throughout the second and third trimesters, those infants born at 
22 to 25 weeks are especially vulnerable to brain injury because of extreme 
immaturity. 
Tyson and associates (2008) reported female gender, singleton pregnancy, 
corticosteroids given for lung maturation and higher gestational age improved the 
prognosis of infants born at the threshold of viability. 
MC Intire and Leveno, 2008 reported that 80 percent of late preterm births 
were due to idiopathic spontaneous preterm labour or prematurity ruptured 
membranes. Complications such as hypertension or placental accidents were 
implicated in approximately 20% of cases. 
PETRINI and co-workers, 2009, reported the increased rates of adverse 
neurodevelopment in late preterm infants compared with term newborns. Fuchs 
and colleagues (2009) reported respiratory morbidities in preterm infants. 
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PROBLEMS OF PRETERM BIRTH 
 
Apart from survival, appreciable physical and intellectual compromise  
afflicts preterm infants. Eichenwald and Stark (2008) studied extensively on short 
term and long term complications of preterm infants. 
 
SHORT TERM COMPLICATIONS 
 Respiratory Distress Syndrome 
 Bronchopulmonary dysplasia 
 Apnea of prematurity 
 Hyperbilirubinemia 
 Necrotising enterocolitis 
 Immune deficiency 
 Intraventricular haemorrhage 
 Periventricular leukomalacia 
 Retinopathy of prematurity 
 Hypotension 
 Patent Ductus Arteriosus 
 Pulmonary hypertension 
 Anemia of prematurity 
 Hypoglycaemia, cortisol deficiency 
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LONG TERM COMPLICATIONS 
 Reactive Airway Disease 
 Asthma 
 Failure to thrive 
 Short bowel syndrome 
 Cholestasis 
 Respiratory syncytial virus infections 
 Bronchiolitis 
 Cerebral palsy 
 Neuro developmental delay 
 Hearing loss 
 Blindness 
 Retinal detachment 
 Myopia, Strabismus 
 Pulmonary Hypertension 
 Hypertension in adulthood 
 Impaired glucose regulation 
 Increased insulin resistance 
 
             A wide spectrum of causes and demographic factors have been implicated 
in preterm birth .Preterm labour, preterm ruptured membranes, preeclampsia, 
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abruption placenta, multiple gestations, placenta praevia, fetal growth restrictions, 
excessive or inadequate fluid volume, fetal anomalies, amnionitis, incompetent 
cervix, as well maternal medical problems such as diabetes mellitus, asthma, drug 
abuse and pyelonephritis may lead to preterm delivery. 
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PATHOGENESIS OF PRETERM LABOUR 
 
Preterm labour can be physiological process occurring prematurely or a 
process which is pathological occurring due to an abnormal stimulus. 
Aetiology of preterm labour may be multifactorial but evidence of infection 
as an important cause of preterm labour is mounting. The earlier the onset of 
labour the more likely infection is implicated. 
Progesterone withdrawal theory in the process of parturition has been well 
understood in sheep but has not been clearly implicated in us. The reversal of the 
ratio of estrogen - progesterone has resulted in increased synthesis of 
prostaglandins and the subsequent initiation of parturition.  
The molecular basis of initiation of labour is unclear but a number of 
theories have been implicated. 
Progesterone withdrawal, oxytocin stimulation and premature decidual 
activation are important. Regardless of the stimulus the final pathway seems to 
converge towards a central role of inflammatory mediators – CYTOKINES. 
Intra amniotic infections can induce the activation of chemokines and 
variety of cytokines which in turn induce cervical softening, pre term rupture of 
membranes and pre term labour.  There is a recruitment of WBC ‘S in response to 
an inflammation resulting from infection which can subsequently undergo 
activation triggering pre term contractions. There is evidence of increased levels of 
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cytokines in the amniotic fluid in patients with pre term labour having evidence of 
infections. These women who have documented evidence of amniotic infection are 
known to be refractory to treatment with tocolytics   
Progesterone inhibitors (mifepristone ) have been implicated in the 
formation of cascade of inflammatory mediators which trigger labour.  The present 
concept of the role of the hormone progesterone in preventing the occurrence of 
pre term labour has been investigated. 
 Though oxytocin hormone is considered to be vital for the induction 
of labour, its role is negligible in the natural process because neither their levels 
increase before parturition nor their levels decrease with advancement of 
pregnancy. 
Csapo (1961) proposed the progesterone block theory to explain the onset of 
labour. According to him; labour was initiated when the delicate balance between 
myometrial relaxant (progesterone) and myometrial stimulant (estrogen) was 
altered in favour of the latter. 
 Differential production of PGE2 and PGF2 α by the three enzymes 
phospholipases, PGH2 synthase, and 15 hydroxy prostaglandin dehydrogenase 
maintains the balance between uterine activity and quiescence. The decidual 
activation and production of uterotropins initiate parturition (Skinner and Challis, 
1985) 
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When fetal adrenal axis becomes more sensitive to ACTH, there is increase 
in cortisol production, leading to increased 17 hydroxylase and finally decreased 
progesterone. 
Cox and colleagues (1993) found that cytokines (IL1,IL6,TNF alpha ,IL8 are 
released when there is inflammatory response to infection and intra uterine 
bleeding. These in turn stimulate arachidonic acid and prostaglandin production. 
Whatever the mechanism to initiate labour, three physiological processes 
have to occur namely softening and dilatation of the cervix, uterine myometrial 
contraction and weakening and rupture of membranes. 
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           Glycerophospolipids (cell membrane) 
Phospholipases 
↓ 
Arachidonic acid 
Prostaglandin H 2  Synthase 
↓ 
Prostaglandin H2 
↓ 
PGE2   PGF2α 
 
 
MYOMETRIAL CONTRACTION 
 
ROLE OF CYTOKINES IN PRETERM LABOUR 
 
Interleukin , 6 and 8,  and Tumour necrosis factor alpha are involved in the 
dissolution of the collagen fibres and cause cervical   softening. Ruptures of 
membranes induced by the matrix metallo proteinases are caused by inter leukin 1 
and Tumour necrosis factor alpha.  
 
Inter leukin 1, 2 and 6 cause an increase in prostaglandin concentration and 
induced uterine contractions.  
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Infection is implicated in 40-50% of cases of preterm labour at early weeks 
<30 weeks Holst RM (2005.). Infection induces an inflammatory response 
involving the activation of a number of cytokines and chemokines which in trigger 
preterm contractions, cervical ripening and rupture of membranes. 
Women with documented intra amniotic infection are often refractory to 
tocolytics. Lamont RF (2003). Preterm babies   exposed to cytokines in utero are 
more likely to have lung and brain damage causing bronco pulmonary dysplasia, 
peri ventricular leucomalacia and cerebral palsy YoonBH 2003. 
Increased association between clinical infection and histological amniotic 
infection has been found in women with pre term labour. Both positive membrane 
cultures and increased concentration of the interleukin 6 has occurred in pre term 
labour which has occurred spontaneously. Offenbacher et al has found strong 
association of pre term birth with periodontal infections. Retrospective studies 
conducted on antenatal women who had been treated with anti microbial agents 
have shown to reduce the incidence of pre term delivery. The prospective trial 
conducted in women who had been given antibiotics after a   previous pre term 
labour has shown decreased incidence of pre term delivery. ( Mcdonald  et al 
1997.) 
Carey et al 2000 in his study on pre term labour and antibiotics treatment 
reported an increased rate of pre term birth in women who were randomized to get 
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metro nidazole. These trials emphasize the complexity of infection and pre term 
labour which is explained by ascending infection which occurs in the antenatal 
period. Host defense mechanisms were also implicated in the causation of pre term 
delivery.   
 
REASONS FOR PRETERM DELIVERY 
 
THE FOUR MAIN DIRECT REASONS FOR PRETERM BIRTHS 
 
1. Delivery for maternal or fetal indication in which labour is induced 
or the infant is delivered by pre labour caesarean delivery. 
2. Spontaneous unexplained preterm labour with intact membranes 
3. Idiopathic preterm premature rupture of membranes 
4. Twins and higher order multi fetal births Goldenberg RL (2002) 
 
Of Preterm births 30 to 35 percent are indicated, 40-45 percent are due to 
spontaneous preterm labour and 30 to 35 percent follow preterm rupture of 
membranes (Goldenberg and colleagues 2008b) 
Medical and obstetrical Indications 
Ananth and Vintzileos (2006) analysed factors leading to indicated birth 
before 35 weeks.  
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COMMON INDICATIONS FOR MEDICAL INTERVENTION RESULTING   
IN PRETERM   LABOUR 
 Preeclampsia 
 Fetal distress 
 Small for gestational age 
 Abruptio placenta 
 Less common causes 
 Chronic hypertension 
 Placenta praevia 
 Diabetes 
 Renal disease 
 Rh isoimmunization 
 Congenital malformation 
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ETIOLOGY OF PRETERM LABOUR 
About 50 -60% preterm births occur following spontaneous  labour, 30% is 
due to preterm rupture of membranes and rest are iatrogenic.(Goldenberg RL 2002; 
Leitich H 2006). 
Meis and colleagues 1996 analyzed the causes and found that one third were 
indicated deliveries for maternal and fetal benefit. 
  One of the major reasons for preterm birth is increase in multiple 
pregnancies (fertility drugs and artificial reproductive techniques and increased 
surveillance and intervention in high risk pregnancies (Ian Doland 6th edition). 
Multifetal gestation has a greater risk for almost every  obstetric complication that 
could occur ,and preterm labour is  one the common problems encountered .There 
has been a report of triplet gestations being managed conservatively  having a 
mean gestational age of 31 weeks. 
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INFECTION 
 
1. UTERINE 
 
Ledger and Bobitt first suggested that unrecognized chorio amnionitis may 
be causally related to preterm labour. They documented positive cultures via trans 
cervical needle aspiration or intrauterine catheters. As many as 50% of 
spontaneous preterm births may be associated with infection (Klein LL, Gibbs RS 
2005) the common pathway of intra uterine infection is the ascending route. 
Colonization of genital tract with group B Streptococcus infection is 
associated with preterm labour. (Bobitt and al Lamont et al).Very often Group B 
streptococcus has been related to the causation of preterm labour and preterm 
rupture of membranes. The current recommendation is to screen high risk women 
and to treat with antibiotics.  
Colonization with Chlamydia trachomatis (Martin et al, Harrison et al)  
Mycoplasma hominis and urea plasma  urealyticum (Klein et al 2008) is associated 
with preterm labour 
Asymptomatic bacterial vaginosis and trichomonas vaginalis infection 
confers modest risk of preterm labour. Bacterial vaginosis (Gravett et al) has 
association with low birth weight. 
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Edward et al, reported higher incidence of positive gonorrhea culture in 
preterm labour 
Presence of infection in the genital tract either as a result of overgrowth of 
normal bacterial flora or abnormal vaginal flora at 26-32 weeks gestation has been 
shown to be associated with preterm labour (Kiss et al 2004.) 
23 percent of neonates born between 23 and 32 weeks have positive 
umbilical blood cultures for genital mycoplasmas (Goldenberg and collegues 2008 
a) Morency and Bujold (2007) suggested that antimicrobials given in second 
trimester prevent subsequent preterm birth. 
 
Bacterial Vaginosis 
 
In this condition, normal hydrogen peroxide producing, lactobacillus 
predominant vaginal flora is replaced with anaerobes such as Gardnerella vaginalis 
and Mycoplasma hominis.The main complaints of bacterial vaginosis is thin 
watery vaginal discharge with fishy odour.,though majority of women remain 
asymptomatic.There has been contradictory studies reporting the beneficial effects 
of screening  the women  belonging to low and high risk groups.There are some 
studies implicating the cytokine production and subsequent activation of the cervix 
and membranes  due to bacterial vaginosis. 
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Environmental factors have been associated with the development of 
bacterial vaginosis. Exposure to chronic stress, ethnic differences, and frequent or 
recent douching have been associated with increased rates of the condition 
(Culhane and workers2002; Ness and associates 2002) 
Condition shown to increase preterm delivery (Flynn et al 1999) risk appears 
to be almost double when detected in early pregnancy (21 percent) compared to 
later in pregnancy (Joesoef at al 1993; Leitich et al 2003) 
Hillier 1995; Kurki 1992, Leitich 2003 proved association of bacterial 
vaginosis with spontaneous abortion, preterm labour, preterm rupture of 
membranes  and chorioamnionitis. 
A gene environment interaction was identified by Macones and colleagues 
2004. Women with bacterial vaginosis and susceptible TNF-Α genotype had a 
ninefold increased incidence of preterm birth 
However Okun and associates (2005) in their systematic analysis on use of 
antibiotics given for bacterial vaginosis found no supporting evidence to prevent 
preterm labour in either low risk or high risk women. 
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EXTRAUTERINE 
 
Robertson et al (2008) reported high prematurity rate with asymptomatic 
bacteruria 
Systemic illness like pneumonia, pyelonephritis, and periodontal disease is 
associated with preterm labour (Xiong X 2006).Appendicitis has also been 
implicated in the causation of preterm labour as stated by some studies. Oral 
bacteria and periodontal infection have been found to be present in women 
developing preterm delivery. 
Vergnes and Sixoci (2007) reported a strong association between periodontal 
disease and preterm birth. Golpfert (2005) in his study found an increased 
incidence of preterm labour in patients having periodontal infection. 
 
1.  PLACENTAL 
 Abnormal  placentation 
 Anatomical abnormalities 
 Placenta praevia 
 Abruptio placenta 
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2. UTERINE 
 Congenital abnormalities 1-3% especially septate and bicornuate uterus 
 In competent cervix and cervical anatomical abnormalities 
 Over distension of uterus 
 
Multifetal gestation is said to be linked with the occurrence of preterm 
labour. Premature uterine contractions are said to occur due the premature 
activation of the gap junctions, prostaglandin production and collagenase activity 
occurring in these conditions. The raised levels of the hormone relaxin, transfer of 
infections during instrumentation of the cervix are some factors relating to the 
occurrence of preterm labour, in assisted reproductive techniques. 
The occurrence of uterine anomalies is generally less than one percentage. 
Michalas 1991; Raga 1997 reported any structural anomaly that alters the 
uterine cavity is likely to cause miscarriage, preterm labour or   mal presentation of 
fetus.  
 
3. GENETIC  
Genetic factors have a pivotal role in the occurence of preterm delivery. 
Gibson, 2007; Hampton, 2006; Li 2004; Macones, 2004 reported literature 
on genetic variants causing preterm labour.  
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Varner and Esplin, 2005 implicated immune regulatory genes in potentiating 
chorio amnionitis in preterm labour. 
Genes for deicidual relaxin/ fetal mito chondrial tri functional protein 
defects, IL-1, β2 adrenergic receptor gene, Tumour Necrosis Factor α are 
implicated in preterm rupture of membranes culminating in preterm delivery. 
Vaginal bleeding in early pregnancy is associated with preterm labour (Williams’s 
obstetrics 22nd edition) 
 
4. Fetal 
Dolan and colleagues (2007) reported that birth defects were associated with 
preterm birth and low birth weight 
 
5.  Preterm labour of unknown origin (20-30%). 
About 20 -30 % of preterm deliveries occur without any demonstrable etiology.  
 
 EPIDEMIOLOGY 
 
1   RACE 
Goldenberg and colleagues 2008 reported higher risk of preterm birth in 
Black, African – American and Afrocaribbean. 
Black women have increased risk for recurrent preterm birth (Kistka and 
Colleagues, 2007) African American women have an increased rate of pre term 
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deliveries when compared to other races as stated by the Center for Health 
statistics 
In 1996 Genc reported that social and demographic factors did not influence 
the rate of pre term birth in African American women.(2000) 
 
2. AGE  
Preterm labour is more common in extremes of age .Lumley JM et al 1993 
reported high incidence of preterm delivery in women under 17 years and over 35 
years.  
 
3. WEIGHT 
  Poor nutrition, pre pregnancy weight and weight gain during pregnancy play 
a important role in causing preterm labour. Hickly and colleagues 2005 have   low 
maternal prenatal gain is specifically associated with preterm birth. 
 
4. STATURE 
Short statured women have more tendencies to produce small babies 
 
5. SOCIOECONOMIC STATUS 
Women from lower socio economic status tends to be less educated and 
would not have satisfactory general, prenatal and antenatal care (Goffinet F 2005) 
23 
 
Universal effect of low socioeconomic status on health appears to directly 
affect the incidence of preterm labour (Moutquin, 2003)  
 
6. ADDICTIONS 
Women who smoke cigarettes or who abuse cocaine are at increased risk of 
preterm labour (Bens 2004) .Cigarette smoking has resulted in the increased 
incidence of pre term birth under 34 weeks gestation especially those who smoke 
more than 20 cigarettes per day. Smoking was initially implicated in the causation 
of placental abruption, placenta praevia and pre mature rupture of membranes but 
recent studies have proved strong association of smoking in pre term delivery. 
(Cnattingius 1998 ). Shah & Bracken reported that smoking was an important 
etiological factor in the causation  of preterm delivery.Boer et al 1993, Volpe 
studied the increased incidence of pre term birth in women addicted to opiods. 
There has been studies showing  high incidence of preterm labour in women 
who abuse cochaine  ,and it was partly attributed to the abruption caused by  
cochaine addiction.(B oer et al) 
 
 However there are not enough studies relating the risk of pre term labour 
with the consumption of alcohol.  
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7 Occupational hazards 
Those involved in manual work are more prone for preterm labour 
 
PREDISPOSING FACTORS 
1. STRESS 
Psychological factors such as depression, anxiety and chronic stress have 
been reported in association with preterm birth (Copper: 1996, Li 2008, Littleton 
2007.Careers which involve considerable physical work and physical work and 
psychological stress are associated with increased preterm births (Papiernik and 
Kaninski 1994).Prolonged standing decreases the utero placental flow and 
increases the frequency of large placental infarcts causing growth retardation. 
Preterm birth is increased in women living alone, and those who are subjected to 
physical abuse. Henrikson et al 1995 reported that heavy vigorous exercise in the 
third trimester increased the risk of pre term delivery  while regular and moderate 
exercise were actually showing a reduced risk. 
 
2. COITUS 
Yost NP et al in 2007 reported that coitus was not found to be associated but 
increasing numbers of sexual partners increased the risk of recurrent preterm 
delivery.  
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3. Reproductive history 
a) Previous preterm birth 
Spong, 2007 concluded prior preterm delivery to be a major risk factor for 
preterm labour. 
History of one previous preterm birth is associated with a recurrence risk of 
16-41 % (Williams 22nd  edition) Risk increases with the number of preterm birth 
and decreases with the number of term deliveries.There is an increase in the risk of 
preterm delivery whenever there is a history of previous preterm delivery.This risk 
is on a increasing trend  whenever the number of prior preterm births 
increases.(Hoffman 1981). When compared to a woman who has got a previous 
term delivery,women  having a prior preterm delivery have threefold times the risk 
of reccurence.This risk becomes eight fold  whenever there is a history of two 
preterm deliveries.Some of the integral factors that may contribute to the 
reccurence are  the cervical length and inherent biological property of the cervix. 
 
b) Previous abortion  
There is increase in the preterm deliveries in women who experienced one or 
more second trimester abortions 
c) Cervical incompetence 
d) Uterine anomalies 
e) Pregnancy complications 
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 Multiple pregnancies 
 Hydramnios 
 Preeclampsia 
 Antepartum haemorrhage 
 Second trimester bleeding not due to placental causes 
 
 
4) Interval between pregnancies                                                                                                   
Intervals shorter than 18 months and longer than 59 months associated with 
increased risk for preterm & small for gestational age infants (Conde – Agudelo 
2006) 
A significant increase in preterm births was observed when the interval 
between birth and LMP of next pregnancy was less than 3 months 
Three fold increase in risk with a previous preterm compared to a previous 
term pregnancy (Bloom et al 2001) 
A previous occurrence of preterm birth before 34 weeks may increase the  
risk of recurrence (Krymko et al 2004) 
 
5)  Fetal Gender 
Fetal factor influencing the rate of preterm delivery is fetal sex, with 
preponderance of males  delivering preterm. 
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MULTIPLE PREGNANCIES  
Preterm delivery occurs in 43.6 percent of all term deliveries compared to 
5.6 percent in singleton pregnancies (Patel et al 1983) 
Monochorionicity has a greater association with preterm labour. 
 
                                   PREDICTION OF PRETERM LABOUR 
 
RISK SCORING SYSTEM 
Creasy and Govik had devised a risk scoring system for preterm labour. 
Women with scores of more than 10 or more are were considered to be at high risk 
for preterm labour. 
Scoring systems are based on the factors which increase the risk of preterm 
delivery, the highest with a previous preterm delivery.  Bleeding in pregnancy 
urinary tract infections, higher order pregnancies, body mass index < 20kg/m2 
previous low birth weight babies and stress  are associated with preterm delivery. 
Unfortunately risk scores don’t identify the majority of women who deliver 
preterm .They are of limited clinical use (Honest H et al 2003)  
Hueston 1995; Mercer 1996 studies failed to show any benefit from risk 
scoring systems. 
As per ACOG 2008, Screening for risk of preterm labour other than risk 
factors is not beneficial in the general obstetric population. Owing to the low 
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predictive value of the risk factors, scoring systems have been identified to be of 
less value.However women presenting with some of the major clinical risk factors 
should be considered to be at risk of preterm delivery. 
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PAPIERNIK SCORING SYSTEM 
 
 
 
Points 
Socioeconomic factors Previous Obstetric 
/ Medical History
 
Social 
Aspects of 
current 
Pregnancy 
1 Two living children 
low socioeconomic 
status 
H/o 1 abortion 
/less than 1 year of 
last child birth 
 
Employed 
 
Unusual fatigue  
2 Maternal age <20 or 
>40 years /single parent
 
H/o 2 abortions 
Smoker 10 
Cigarettes / 
day/ 
moderate 
work 
Gain <5g by 32 
weeks 
3 Very low 
socioeconomic status 
Ht < 150cm wt < 45 kg 
 
 
H/o 3 abortion 
Heavy work 
/ long 
distance 
travelling 
Breech 32 weeks 
/ weight loss 
/head engaged at 
32 weeks/febrile 
illness
4 Maternal age <18 years  
 
Pyelonephritis 
 Bleeding after 12 
weeks / short 
cervix open 
internal OS 
uterine  
irritability  
5  Uterine anomaly 
second trimester 
abortion /DES 
exposure/cone 
biopsy 
 Placenta Praevia 
Hydramnios 
6  Preterm delivery 
,repeated second 
trimester abortion
 Twins / 
abdominal 
surgical 
procedure 
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CERVICAL ASSESSMENT 
 
CERVICAL DILATATION 
Papiernik and colleagues (1987) in a study of cervical status before 37 
weeks found that precocious cervical dilatation increased the risk of preterm 
labour. Levino and associates found that one fourth of the women who cervices 
were dilated 2 to 3 cm between 26 and 30 weeks delivered before 34 weeks 
Asymptomatic cervical dilatation after mid pregnancy has gained attention as a risk 
factor for preterm labour 
Copper and associates 1995; Pereira and colleagues, 2007 verified cervical 
dilatation as a predictor of increased preterm delivery risk 
 
CERVICAL LENGTH 
 I am and coworkers (1996) reported a mean cervical length at 24 weeks was 
approximately 35mm and those women with progressively shorter cervices 
experienced increased rates of preterm birth. 
 Owen associates (2001) reported a significant correlation of cervical length 
at 16 to 24 weeks and subsequent preterm birth before 35 weeks. They concluded 
in 2003 that the value of cervical length to predict birth before 35 weeks is 
apparent only in high risk preterm birth. 
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 De Carvalho et al 2005 correlated sonographic cervical length, funneling and 
prior history of preterm birth with delivery before 35 weeks.  
 
SONOGRAPHIC CERVICAL SCREENING 
Transvaginal  sonography allows an accurate assessment of cervix and is 
used to improve the accuracy of prediction of a woman going into preterm labour 
(Honest et al 2003) .Cervical length in a low risk population is normally distributed 
,with a mean length at  23 weeks gestation of 35mm to 38 mm, the 10th and 90th 
percentile are approximately 25mm and 45mm respectively. The risk of preterm 
delivery is high if the cervical length was less than 25mm (Hassan et al 2000; To et 
al 2oo1) 
Cook and associates (2000) showed that cervical length less than 21mm at 
less than 20 weeks gestation was associated with 95% delivery by 34 weeks 
gestation in women at high risk of preterm delivery. 
Owen et al (2001) demonstrated that single TVS of cervix at 16 to 19 weeks 
with a cervical length of 25mm or less increased the risk of preterm delivery by 35 
weeks gestation, 3.3 times. 
Though there were studies including cervical funneling and dilatation for 
preterm labour risk parameters , cervical length was the main contributing factor  
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for the prediction of preterm delivery,and a cervical length of 25 mm was an 
important predictive factor.(To et al 2001) 
Andrews et al (2000) found that fortnightly screening was found to be 
significantly helpful in prediction of preterm delivery. 
 
CERVICAL INCOMPETENCE 
 Painless cervical dilatation in second trimester. It can follow prolapse and 
ballooning of membranes and ultimately expulsion of immature fetus. 
CAUSES  Previous cervical trauma – Dilatation and curettage  
Conization 
Cauterization 
 Albrechtsen and colleagues (2008) reported fourfold risk of pregnancy loss 
before 24 weeks. 
 
FETAL FIBRONECTIN 
Glycoprotein produced by a variety of cell types presents in high 
concentrations in maternal blood and amniotic fluid, placental tissue and the 
deciduas basalis. It is normally found in cevico vaginal secretions before 16 to 18 
weeks gestation, before the fusion of fetal membranes and decidua is complete and 
also prior to onset of labour, but not normally present between 22 and 37 weeks 
gestation   
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Plays a role in intercellular adhesion during implantation and for 
maintenance of placental adhesion to uterine decidua (Lesson et al 1996) 
Lockwood and co-workers (1991) reported that fibronectin in cervico 
vaginal secretions prior to membrane rupture were a possible marker for 
impending preterm labour.  
Swabs are taken from the posterior fornix of vagina or the ecto cervix, 
ELISA with FDC 6 monoclonal antibody is used for the detection of fetal 
fibronectin . 
 Using ELISA technique, a value exceeding 50 ng/ml is considered positive.   
Quantitative tests take longer duration; therefore bed side tests have been 
developed in recent times to detect the presence and absence of fibronectin. 
However of concern is the high false positive rate if there is contamination with 
amniotic fluid, semen, and maternal blood and in patients with cerclage, rupture of 
membranes and pre eclampsia . Goldberg and coworkers 2000 reported, positive 
cervical or vaginal fetal fibronectin assay as a powerful predictor of preterm birth. 
The test is more accurate in predicting spontaneous preterm birth within 7 -10 days 
in women with symptoms of threatened preterm labour before cervical dilatation. 
Absence of fetal fibronectin carries a low risk in the occurrence of pre term births. 
But the utility of fetal fibronectin has been low in population with low risk 
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however combination of fetal fibronectin with clinical scoring has increased the 
positive prediction rate of pre term labour. 
 
BIOCHEMICAL MARKERS 
1) Salivary ostriol: progesterone ratio 
2) Salivary oestriol > 1.8/ml before 34 weeks  has sensitivity of 68% and 
specificity of 76% for preterm labour before 35 weeks of gestation(Darne 
et al) 
3)  Serum collagenase 
4) Tissue  inhibitor of metalloproteinase (TIMP)/Matrix metalloproteinases 
5) Relaxin 
6) Corticotrophin Releasing Hormone 
7) Human chorionic gonadotrophin 
These are of less practical value in prediction of preterm labour 
 
Mediators of Inflammation And Infection 
a. C – Reactive protein 
b. Granulocyte elastase 
c. Cytokines ( IL-6, TNF) 
d. Amniotic Fluid Glucose Concentration  
e. Zinc 
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f. Lipocortin -1 (Romeo R et al ) 
g. Positive cultures 
h. Granulocyte colony stimulating factor 
These are not practically helpful in prediction of pre term labour 
 
Fetal Breathing Movements  
 Absence of fetal breathing movements detected on ultra sound at the 
time of admission on women who presented with threatened pre term labour was 
found to be an accurate test in the prediction of spontaneous pre term labour. 
 
Uterine Activity Monitoring  
Although teaching a woman to self monitor her uterine contractions is a 
simple inexpensive method, there are lot of subjective variations in it which makes 
it less reliable .One of an earlier case control study reported a decrease in the 
preterm delivery rates on using the ambulatory monitoring system.(Katz et al 
1986). 
 Currents opinion is that for most patients home uterine monitoring is 
no better than frequent nursing care and support.  Only patients, who cannot 
recognize the presence of uterine contractions adequately like multi fetal gestation 
and over distended uterus may benefit from home monitoring.   
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DIAGNOSIS OF PRETERM LABOUR 
Cunningham GH and coworkers (2001) found that preterm  labour is 
established when regular uterine contractions occur at least 4 in 20 minutes or 8 in 
60 minutes with progressive change in cervical score with effacement 80% or more 
and dilatation more than 1 cm contraction are 5 to 8 minutes apart. 
Threatened preterm labour is a condition in which uterine contractions occur 
in the absence of cervical changes  
 
SYMPTOMS 
 
 Menstrual like cramps 
 Low dull back ache 
 Increase or change in vaginal discharge 
 Uterine contractions 10 minutes apart or closer 
 
4) Tococardiography 
 
The amplitude, duration, shapes of contraction frequency and basal tone are 
monitored .The uterine activity is monitored. 
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Repetitive late decelerations, absent variability and variable decelerations 
are a sign of placental insufficiency. 
 
 PREVENTION OF PRE TERM LABOUR 
Prevention is an important strategy in the management of a patient at high 
risk of preterm labour. 
 
BASIC CARE 
Development of family support, education, supportive services from health care 
providers 
 Behavioral, life type modifications 
 Cessation of smoking (Burguet et al) 
 Adequate nutrition. 
 Avoidance of illicit drugs 
 
BED REST, HYDRATION AND SEDATION 
Although bed rest and hydration are widely used as the first step of    
prevention, its practical benefit has been debatable. (Golden berg RL et al) 
Kovacevich et al in his studies showed that bed rest of more than three days 
was associated with an increased occurrence of thrombo embolic events in women 
with threatened pre term labour.  
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Some studies have reported the increased risk of development of pulmonary 
edema, when intravenous fluids are administered during tocolytic therapy. There is 
no substantial evidence of hydration therapy in causing pregnancy prolongation. 
Hydration therapy however has been rarely studied as a single therapy in 
prevention or treatment of pre term labour. 
 Cochrane systematic review showed no significant difference in the risk of 
pre term labour in women who received hydration therapy.  
Comparative trials have been conducted between combination of sedation 
with hydration vs intramuscular opiods in reducing the occurrence of preterm 
delivery and the results were found to be similar in both groups. 
 
 
TREATMENT OF INFECTIONS 
About 25 – 40 percent of preterm births are estimated to result from 
intrauterine infections (Cunningham et al 2010) 
Morency and Buyold (2007) seemed to indicate that antibiotics given in the 
second trimester to women with a history of preterm labour would be effective in 
preventing recurrence of preterm labour    
Most Randomized control trials show that intra vaginal clindamycin cream 
used to treat bacterial vaginosis did not   preterm birth. Carey et al (2000) used oral 
metronidazole to treat bacterial vaginosis but did not find a reduction in preterm 
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birth. Systematic review concluded that screening and treatment of asymptomatic 
bacteruria and bacterial vaginosis may reduce the incidence of preterm in low risk 
population 
 
CERVICAL ENCERCLAGE 
 
Primary cerclages are placed prophylactically in women considered at high 
risk of preterm birth based on obstetric history 
Secondary cerclages are placed when ultrasound findings are indicative of 
cervical insufficiency in high risk women 
Tertiary cerclages are performed as an emergency procedure in the presence 
of positive clinical examination findings 
The 1993 MRC/RCOG Multicenter Randomized trial concluded that clear 
benefit was seen only in patients with a history of three or more spontaneous births 
or preterm deliveries (Mac Naughton et al 1993) 
In 2001, CIPRACT Trial, Cervical Incompetence Prevention Randomised 
Cerclage Trial showed that patients with cervical insufficiency and cerclage 
placement had a lower incidence of preterm delivery prior to 34 weeks 
(ALTHUISIUS ET AL 2001)  
Rest et al 2000 concluded that cerclage failed to alter any perinatal outcome 
Daskalakis et al (2006) reported the benefits of emergency cerclage. In preterm 
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labour  Dor et al 1982 and Roman et al 2005 reported that elective cerclage  had no 
benefit in twin gestation . Two randomized trials by Lazar et al and Rush et al 
showed no benefit of routine cerclage in women at moderate risk for preterm 
labour.  
 
PROGESTERONE   
 
Progesterone given as weekly intramuscular injections of 17 α hydroxyl 
progesterone caproate from 16-20 weeks to 37 weeks showed significant reduction 
in preterm labour (Meis et al 2003) .It is not beneficial in twin pregnancies (Rouse 
et al 2007) (.Fonseca et al 2007) Micronized progesterone for asymptomatic 
women with very short cervix (less than 15mm) appear to be effective for 
prevention of preterm delivery. 
As per ACOG (2008) progesterone is not recommended as a supplementary 
treatment to cervical cerclage for suspected cervical insufficiency or .as a 
preventive agent for asymptomatic women with a positive fetal fibronectin screen 
result or as a tocolytic agent. The role of progesterone in threatened preterm labour 
is uncertain. (Cochrane Systematic Review 2006) 
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                             MANAGEMENT OF PRETERM LABOUR 
 
ROLE OF CORTICOSTEROIDS 
 
In 1995 National Institute of Health consensus Development Panel 
recommended corticosteroids for fetal lung maturation in preterm infants. antenatal 
corticosteroids are recommended for all pregnant women between 25 and 34 weeks 
who are at risk of preterm delivery within 7 days  
Cochrane systematic analysis reported that antenatal corticosteroids reduce 
neonatal death respiratory distress syndrome, intra ventricular hemorrhage, 
necrotizing enter colitis in first 48 hours of life as well as reduction in the need for 
intensive care monitoring & respiratory support later. 
Though the maximum benefit of corticosteroid administration is between 24 
hours and 7 days after initiation of therapy they provide surgical advantage even 
when baby is delivered within 24 hours.  
Roberts and Dalziel (2006) reviewed antenatal corticosteroids for 
accelerating fetal lung maturity Bruschettini and colleagues (2006) studied 
equivalent of 12 mg versus 6 mg beta methadone and reported that the lower dose 
had less severe effects on somatic growth without affecting cell proliferation Eli 
main and co workers (2007) reported that beta methasone and dexamethasone were 
comparable in reducing the rates of major neonatal mortalities in preterm infants  
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TOCOLYTIC AGENTS 
Tocolysis is pharmacological suppression of uterine activity. 
Tocolytic drugs have been used in an attempt to inhibit preterm labour.  
They are effective in reducing the likelihood of delivery within 48 hours but do not 
reduce the overall risk of preterm labour. (ACOG 2007) 
Tocolytics may be required 
1. To gain 48 hours to administer antenatal steroids for increasing    
     pulmonary maturity 
2. To permit in utero  transfer of the patient to a tertiary care centre for  
              Multidisciplinary management 
3. Prepare for neonatal care 
4. Preparing the patient for an operative delivery 
Variety of drugs which act on uterine smooth muscle to interrupt 
contractions are available these include magnesium sulphate, calcium channel 
blockers, oxytocin antagonists, Non steroidal anti inflammatory drugs (NSAIDS) 
and beta mimetic agonists 
As per ACOG 2003, choice of tocolytic agent is individualized and is 
usually based on the maternal condition. 
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β SYMPATHOMIMETICS 
 
Cartis et al noted that small dose of epinephrine inhibited uterine 
hyperactivity .Efforts to produce an epinephrine like compound which lacked the 
cardiovascular stimulant effect culminated in the synthesis of beta agonists 
 They react with β adrenergic receptors to reduce intracellular ionized 
calcium levels and prevent activation of myometrial contractile proteins Beta 
mimetics can cause mild fall in diastolic blood pressure and is used cautiously in 
patients of ante partum hemorrhage. they also cause a slight increase of blood 
sugar in non diabetic patient and hence can cause gestational diabetes when  used 
for a longer duration alter thyroid function, elevated trans aminases hypo calcemia, 
anti diuresis and hypo kalemia are the other metabolic effects of beta mimetics. 
Some of the neonatal side effects of beta mimetics include increased risk of 
hypo calcemia, hypo glycemia and intraventricular haemorrhage. 
In recent time better drugs have replaced beta mimetics in regard to tocolytic 
function due to better profile of safety and less of adverse effects. 
 
Classification 
 
1st   generation: Isoxsuprine, Orciprenaline, Isoprenaline,  
2nd generation : Ritodrine, Terbutaline, Fenoterol  
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The most common used beta 2 agonist for tocolysis is ritodrine; then is terbutaline 
and salbutamol. 
 
RITODRINE: 
 Merkatz and colleages 1980 achieved a gestational age of 36 weeks in 
patients treated with ritodrine for threatened preterm labour. 
 It is given as infusion at a dose of 50 µg/min and increased every 20 minutes 
until uterus is quiescent or side effects limit escalation of dose. 
 However the drugs have been implicated as a cause of increased capillary 
permeability, disturbance of cardiac rhythm and myocardial ischemia. 
 Side effects are palpitations, tremor, nausea, headache, chest pain dyspnea, 
pulmonary edema, hypokalemia, myocardial ischemia and arrhythmias. 
 Ritodrine was withdrawn voluntarily in 2003, according to Federal Register, 
United States owing to its adverse effects  
 
TERBUTALINE 
 Not used as much as ritodrine, but   is effective in temporary suppression of 
uterine contractions when given parenterally. 
 Intravenous dose 5-10 µg/min ,increased every 10-15 min to a maximum of 
80 µg. 2.5 – 5 mg is the oral dose given every 4-6 hours and  250µg 
subcutaneously every 20-30 minutes given as 4-6 doses.  
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 Terbutaline causes more hyperglycemia than ritodrine 
Like ritodrine it can cause pulmonary edema (Angel and associates 1988) 
Gunin and associates (1998) reported no significant prolongation or improved 
neonatal outcome with terbutaline is not approved by the FDA and therefore its not 
mentioned in any protocol for pre term labour. 
Β2 agonists are no longer the first choice of drugs because of their side 
effects (RCOG 2002, Anotayanoth et al 2004) 
Contraindications of beta 2 agonist :symptomatic cardiac disease, 
conduction disturbance, hyperthyroidism, sickle cell disease, uncontrolled diabetes 
mellitus, chorioamionitis, severe preeclampsia, multifetal gestation and severe 
obstetrical bleeding 
 
Prostaglandin Inhibitors  
Acetylsalicylate (Aspirin), Indomethacin naproxen fenamate, sulindac 
inhibit prostaglandin syntheses enzyme responsible for the conversion of free 
arachidonic acid to prostaglandins thereby decrease the myometrial gap junctions 
and influx of calcium. 
 Indomethacin was first used as a tocolytic by Zuckerman and associates 
(1974) various trials compared indomethacin with other drugs like ritodrine; 
Magnesium sulfate and found no difference in efficacy (Morales and coworkers 
(1989, 1193a) 
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 Indomethacin is administered orally or rectally. A dose of 50 to 100 mg at 5 
hours intervals, not to exceed 200 mg in 24 hours period. 
 Adverse effects reported are oligohydramnios, pulmonary hypertension due 
to constriction of ductus arteriosus. Intra cellular hemorrhage, necrotizing 
enterocolitis have also been reported. 
 Two randomized trials which compared the effect of indomethacin and 
placebo in delaying delivery showed no significant delay at 48 hours and 7 – 10 
days. 
 
 
Magnesium sulphate 
  Ionic magnesium in a sufficiently high concentration can alter myometrial 
contractility. Its role is presumably that of a calcium antagonist causing less 
intracellular calcium (Ca2+) to participate in actins myosin interaction during 
smooth muscle contraction. 
Elliott in his study found that Magnesium sulphate was effective tocolytic in 87% 
cases. 
Cox and associates in their study did not report any differences in the pregnancy 
outcome using magnesium sulphate. 
 It affects neural transmission by modifying acetyl chloline release and 
sensitivity of motor end plate.  
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Drug concentration and effect 
 Contractility is inhibited at serum level of 5 – 8 mEq/L. 
 Deep tension reflexes are lost at 9 – 13 mEq/L. 
 Respiratory depression occurs at > 14 Meq/ dl 
Loading dose of 4g IV given over 20 minutes followed by maintenance dose of 
1 – 2 g / hour. 
 Side effect is nausea, giddiness, flushing, hypocalcaemia, respiratory 
depression, pulmonary edema and depressed motor respiratory activity in fetus. 
 Contraindications of magnesium sulfate are myasthenia gravis, heart block, 
renal disease and recent myocardial infarction  
 Neuro protective effect of magnesium sulfate was evaluated in (BEAM 
study-Beneficial Effects of Antenatal Magnesium Sulfate) 
 According to Gowther et al 2002, Cochrane systematic review, magnesium 
sulfate is an ineffective tocolytic. 
Wilkens et al 1989 reported the occurrence of significant side effect of magnesium 
sulphate while being used concurrently with beta mimetics for tocolysis .  
 
CALCIUM CHANNEL BLOCKERS 
 These agents act by reducing the influx of calcium ions into the cell 
membrane during the inward calcium current of action potential. They block the 
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voltage sensitive L type of calcium channels. They  also decrease the tone of 
smooth muscles  by inhibition of intracellular calcium from sarcoplasmic reticulum 
.Nifedipine is the most commonly used calcium channel blocker. 
 King and colleagues 2003, Papatson’s 1997 concluded than calcium channel 
blockers especially Nifedipine are safer and more effective tocolytic agents than 
are beta agonists and have lower neonatal morbidity No significant change in utero 
placental flow has been reported .Mari et al (1989) 
 
TREATMENT REGIMEN 
 
 Optimal dose regimen of Nifedipine has not yet been defined 
 George et al 1991, Read and Wellby (1986), showed that initial dose of 30 
mg followed by 20 mg 8th hourly for 3 days had a success rate of 75% Andrenne et 
al gave a dosing regimen of 30 mg oral followed by a maintenance dose of 10 – 20 
mg orally every 4 – 6 hours.  
 Most trials advocated an initial loading dose of 30 mg of oral Nifedipine 
followed by 10 to 20 mg every 6 hours. Sublingual Nifedipine is no longer 
advocated due to risk of sudden hypotension. Onset of action is less than 20 
minutes with peak plasma concentration within 15 – 90 minutes. 
 Having a half life of 1.5 to 3 days. Elimination is mainly through kidneys 
(70%) and bowel 30%. Though the duration of action of a single dose can be as 
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long as 6 hours, there is no apparent cumulative effect when administered every 6 
hours. 
 Side effects include facial flushing, nausea vomiting, headache, hypotension 
and tachycardia. No significant alteration in blood glucose and serum electrolytes 
was reported. 
 
OXYTOCIN ANTAGONIST (ATOSIBAN) 
 Nonapeptide oxytocin analog is a competitive antagonist of oxytocin 
induced contractions. 
Dosage: Recommended dose and administration schedule is a three step 
procedure. The initial bolus dose is 6.75 mg given over one minute, followed by an 
infusion of 18 mg/hour for three hours and 6 mg/hour for up to 45 hours. 
Treatment should not last longer than 48 hours and total dose given should not 
exceed 330 mg (RCOG, clinical Guidelines 2002) 
Side effects include nausea, vomiting, chest pain, and dyspnoea 
In randomized clinical trials, artesian failed to improve relevant neonatal 
outcome and was linked with significant neonatal morbidity (Moutquin and 
coworkers, 2000 Romero and associates 2000) 
However, RCOG clinical guidelines 2002 suggested the first choice on 
administration of tocolytics to be oxytocin antagonist or Nifedipine. 
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NITRIC OXIDE DONORS (GLYCERYL TRINTRATE) 
 It is a potent   endogenous hormone having smooth muscle relaxant 
property. Main action affects vasculature, gut and uterus. 
NO donors act by inhibiting CRH (Corticotrophin releasing hormone, a promoter 
of parturition. 
 Dosage 10 mg Glycerol Tri nitrate patch placed over fundal region of 
maternal abdomen. Dose can be repeated with another 10 mg after one hour, if 
tocolysis is not achieved, to a maximum dose of 20 mg in 24 hours 
Maternal hypotension is a common side effect.   
In randomized clinical trials, Nitro glycerin administered orally, trans dermal 
or intravenously was not effective and was no superior to other tocolytics (Bistis 
2004, Clavin 1996, Rees 1999, Buhimschi 2002. Duckitt K et al reported that 
nitroglycerine did not improve neonatal outcome or delay delivery on comparison 
with placebo, no treatment or alternative tocolytics. 
POTASSIUM CHANNEL OPENERS 
Diazoxide is related to thiazide diuretics and its main use is in the treatment 
of malignant hypertension. Its mechanism of action is inhibition of smooth muscle 
contractility, thereby causing uterine quiescence. 
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It is given in a dose of 5mg / kg, slow intravenous over 20-30 minutes. The 
drug is given after diluting with saline. Bolus dosage includes 50 -100 mg given 
every 5 minutes. 
Side effects are tachycardia,   
hyperglycaemia, decreased blood pressure, and decreased utero placental 
flow secondary to hypotension in the mother. Hypoglycaemia and fetal distress are 
the side effects which occur secondary to maternal hypotension. 
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AIM OF THE STUDY 
 
1. To evaluate the Tocolytic effects of Calcium channel blocker – 
NIFEDIPINE in preterm labour  
2. To study the maternal and fetal effects of NIFEDIPINE. 
3. To compare the efficacy of Nifedipine  with control group in delaying 
delivery  for 48 hours in  idiopathic  spontaneous preterm labour 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
It is prospective study conducted in Government RSRM Lying in Hospital, 
Stanley Medical College, and Chennai, from September 2012 to September 2013 
The study population comprised of patients who attended the causality or outpatient 
department. There were 100 patients in Nifedipine group and 2 patients were lost to 
follow-up. There were 100 patients in Control group and 3 patients were lost to 
follow up. Study group received Nifedipine and control group were observed with 
bed rest. Both groups received intra muscular corticosteroids. Written informed 
consent obtained. 
 
INCLUSION CRITERIA 
1. Gestational age between 28 and 34 as determined by menstrual dates, clinical 
examination, and ultra sonogram  
2. Uterine contractions 4 contractions in 20 minute period lasting for 40 – 45 
seconds. 
3. Cervical effacement of 75% 
4. Cervical dilatation < 3 cm  
5. Intact membranes. 
6.   
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EXCLUSION CRITERIA 
Maternal Conditions 
 GA > 34 Weeks 
 Rupture of membranes 
 Evidence of chorioamnionitis  
 Cervical dilatation greater than 4cm 
 Ante partum hemorrhage  
 Polyhyramnios / oligohydramnios 
 Pregnancy induced hypertension 
 Chronic hypertension 
 Previous caesarean section 
 Cardiac disease 
 Renal disease 
 Uncontrolled diabetes mellitus 
 Asthma, Adult Respiratory distress Syndrome  
 History of allergy 
 Liver disease 
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FETAL CONDITION  
 Multiple gestations 
 Fetal death / distress 
 IUGR 
 Congenital anomalies 
. 
INVESTIGATIONS 
 Urine analysis 
 Complete blood count 
 High vaginal swab 
 USG Abdomen 
 ECG (Electrocardiogram) 
 
DRUG PROTOCOL 
 
On admission, patients were put in left lateral position. Temperature, pulse 
rate and blood pressure recorded .Cardiovascular system and Respiratory system 
examined.  
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GROUP A 
 
Tab. Nifedipine 20 mg was given orally. If uterine contractions persisted 
after 90 minutes another 10 mg dose given. If the dosage suppressed uterine 
activity then maintenance of 10 mg given 6th hourly for 3 days. Dosage is gradually 
tapered and stopped. 
If uterine contractions did not cease within 1-1/2 hours patient was deemed 
failure and treatment stopped .Treatment considered success if there was abolition 
of uterine contractions and progress of cervical dilatation and postponement of 
labour for at least 48 hours. 
 
GROUP B 
 Patients observed with bed rest 
 Both the groups given intramuscular corticosteroids 
 
 Monitoring of vitals – Temperature, Pulse rate 
 Blood pressure Respiratory rate 
 
 Systolic BP<100 mm Hg or pulse rate > 100, 
 Temperature > 37.5°C is important 
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 Careful watch for side effects like facial flushing ,tachycardia, hypertension, 
nausea and vomiting 
 
After initial reactive CTG (Cardio tocography), fetal heart rate monitored 
hourly during stabilization phase and there after fourth hourly for first 48 hours  
 
Success and Failure 
There are several studies by various authors suggesting several factors for 
assessment of success of tocolysis.  
In our study, successful tocolysis was defined as the delay of delivery with 
suppression of contractions for more than 48 hours from initiation of therapy.  
Failure of therapy is said to occur, when patient delivered within 48 hours of 
initiation of therapy and tocolysis was stopped when cervical dilatation progressed 
to > 3 cm or when there was spontaneous rupture of membranes.  
Hence our study is confined to idiopathic spontaneous preterm labour and 
comparing the efficacy of Nifedipine with that of control in delaying delivery for 
48 hours and regarding the maternal and fetal effects of Nifedipine  
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RESULTS 
AGE DISTRIBUTION 
Table: 1 
 
Age in 
years 
Nifedipine group Control group Percentage
No. % No. % % 
<19 12 12.2% 16 16.4 14.36 
20 – 24 34 34.6 43 44.3 39.4
25 – 29 43 43.8 31 31.9 38.14
>30 9 9.1 7 7.2 8.20 
 
Maximum incidence of preterm labour occurred in age group 20 – 24 years 
being 39.4%. 
Incidence of preterm labour in age group less than 19 years and more than 
30 years was 22.5% 
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ANTENATAL REGISTRATION 
Table: 2 
 
Booked / 
Unbooked 
Nifedipine group Control group 
BOOKED 79 80.6% 84 86.5% 
UNBOOKED 19 19.38% 13 13.4% 
 
 
Incidences of preterm labour in booked and unbooked cases were 83.5%and 
16.44 % respectively. 
 
 
 
 
 
 
 
 
 
60 
 
OBSTETRIC HISTORY 
Table: 3 
 
Gravida Nifedipine group Control group Percentage 
PRIMI 67 68.3% 62 63.9% 66.1% 
PARA 
Iand above 
31 31.6% 35 36% 33.8% 
 
Incidence of preterm labour among primi gravida and multi gravida were 
66.1% and 33.8% respectively. 
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GESTATIONAL AGE 
Table: 4 
 
GA weeks Nifedipine group Control group       percentage
28 – 30 30 30.6% 31      31.28% 
31 – 34 68 69.38% 66      68.04% 
 
Incidence of preterm labour between 28-30 weeks is 31.28 %and between 
31-34 weeks is 68.o4%  
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SUCCESS OF TOCOLYSIS 
Table: 5 
 
 
Success/Failure 
 
Nifedipine group 
 
Control group 
SUCCESS 72 73.4% 32 32.9% 
FAILURE 26 26.5% 65 67.01% 
 
The success in Nifedipine and controls are 73.4% and 32.9% respectively. 
By test of proportion p value was found to be < 0.001 which is statistically 
significant. 
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DOSAGE REQUIRED 
Table: 6 
 
S NO DOSE NO. % 
1. 20mg 21 21.4% 
2. 30mg 77 78.57% 
 
78.57% of patients required 30 mg to suppress uterine contractions whereas 
21.4% required 20 mg to suppress uterine contractions.  
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RESPONSE ACCORDING TO GESTATIONAL AGE 
Table: 7 
 
GA 
weeks 
Nifedipine group Control group 
 S F S F 
 No % No % No % No % 
28 – 30 8 11.1% 22 84.6% 3 9.3% 35 53.84%
31 – 34 64 88.8% 4 15.38.% 29 90.6% 30 46.15%
 
Prolongation of pregnancy more than 48 hours is 88.8% and 90.6% in 31-34 
weeks gestational group between nifedipine and control groups respectively. 9.3% 
and 11.1% in 28-30 weeks gestational group are in control and nifedipine groups 
respectively. 
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DURATION OF PROLONGATION 
Table: 8 
 
DURATION OF 
PROLONGATiON  
Nifedipine group Control group 
No. % No. % 
<48 hours 26 26.5% 65 67.01% 
48 hours 52 53.06% 32 32.9% 
Upto 72 hrs  13 13.2% 0  
Upto 5 days 5 5.1% 0  
Upto  1 week 2 2.o4%   
 
Prolongation of delivery beyond 48 hours was seen in 53.06% in nifedipine 
group compared to 32.9% in control group. Delivery occurred within 48 hours in 
26.5% in nifedipine group compared to 67.01% in control group 
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SIDE EFECTS OF NIFEDIPINE 
Table: 9 
 
   
1 Tachycardia 15 
2 Headache 20 
3 Hypotension 7 
4 Nausea vomiting 10 
5 Facial flushing 3 
 
About 56.1% patients had side effects .Headache and maternal tachycardia was 
commoner among the side effects. 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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FETAL MORBIDITY 
Table: 10 
 
 
 Nifedipine group Control group % 
 S F S F  
BIRTH 
ASPHYXIA 
1 2 2 2 3.5% 
Rds 2 4 4 11 10.7% 
Sepsis 4 3 6 4 8.71% 
IVH 1 1 1 2 2.5% 
 
About 11.1 % and 38.46% of neonatal complications occurred in nifedipine 
success and failure groups respectively. 
About 40.6% and 29.23 % of neonatal complications occurred in control 
success and failure groups. 
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NEONATAL MORTALITY 
Table: 11 
 
 Nifedipine group Control group 
 S F S F 
 6 8 9 13 
 
Neonatal mortality was 14.28 % and 22.8. % among Nifedipine and control 
groups respectively  
OVERALL NEONATAL MORTALITY WAS 18.46% AMONG BOTH 
GROUPS. 
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APGAR SCORE 
Table: 12 
 
  5’ 
APGAR 
Nifedipine group  Control group 
  S  F  S  F 
  No.  %  No.  %  No.  %  No.  % 
≤ 5  3  4.1%  12  46.1%  8  25%  42  64.6%
6‐7  16  22.2%  4  15.3%  6  18.75%  10  24.6%
>7/10  53  73.6%  10  38%  18  56.2%  4  10.7%
 
Among the success groups, 73.6% belonged to Nifedipine, 56.2% belonged 
to control group having apgar >7 
P value <0.001 significant.    
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WEIGHT OF BABY OF BIRTH 
Table: 13 
 
 
BIRTH WEIGHT  Nifedipine group  Control group 
S  F  S  F 
  No  %  No  %  No  %  No  % 
<2  5  6.9%  24  92.3%  12  37.5%  39  60% 
2‐2.5  61  84.7%  2  7.69%  18  56.2%  26  40% 
>2.5  6  8.3%  ‐  ‐  2  6.25.%  ‐  ‐ 
 
84.7% cases among Nifedipine success groups had birth weight of 2-2.5 kg 
when compare with 56.2% in control success group. 
8.3% in Nifedipine success group had birth weight >2.5 kg compared to 
6.25% in control success groups. p value 0.001 statistically significant. 
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RESPIRATORY DISTRESS SYNDROME 
Table: 14 
 
 
RDS Nifedipine group Control group 
 S F S F 
 No. % No. % No. % No. % 
PRESENT 2 2.7% 4 15.38% 4 12.5% 11 16.9%
ABSENT 70 97.2% 22 84.61% 28 87.5% 55 84.6%
 
Incidence of RDS is 2.7% and 15.38% in nifedipine success and failure 
respectively, compared to 12.5% and 16.9% in control success and failure groups. 
P value 0.042.statistically significant 
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DISCUSSION 
 
 In our study the range of gestational age was 28 to 34 weeks. In other studies 
it was 24 to 32 weeks (Nikolov et al) and 26 to 34 weeks (Bekkari et al). In 
Cochrane meta analysis study, the inclusion range of gestational age was from 20 
to 26 weeks upto a maximum of 36weeks. The mean gestational age in Systematic 
meta analysis review was 29.1 to 32.4 weeks. The trials in the Meta analysis 
excluded women with cervical dilatation more than 4cm, while in our study the 
limit was 3cm. 
 In our study the dosage of Nifedipine used as 20 mg of loading dose 
followed by 10 mg at 90 minutes, if uterine contraction persisted, followed by 
maintenance dose of 10 mg of oral nifedipine 6 hourly for 3days. Similar to this a 
loading dose of oral nifedipine 3x10mg was used by Bekkari et al A loading dose 
4x10 mg of oral nifedipine was used by Nikolov et al in their study. 
 In Cochrane meta analyis  the maximum dose used was 40 mg of oral 
nifedipine in the first hour followed by 20mg of slow release nifedipine at t=90 
minutes (Papatsonis et al). 
 Most of the trials in the Cochrane meta analysis measured outcome 
primarily by delay in delivery for more than 48 hours as in our study. 9 out of 13 
trials in this review reported a favorable outcome. Bekkari et al and Nikolov et al 
reported a success of 84% and 86.4% respectively, while in our study it was 73.4% 
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 The most common side effects in the trials in Cochrane meta analysis were 
hypotension and headache similar to our study. Similar to our study there was no 
maternal mortality in any of those trials. No maternal side effects and good patient 
tolerance were reported by Nikolov et al and Bekkari et al respectively in their 
studies. 
 Similar to our study there was a reduction in respiratory distress syndrome 
and improved Apgar scores at 5 minutes in Cochrane meta analysis. According to 
Systematic Review and Metaanalysis on Efficacy and safety of nifedipine for 
management of preterm labour  (2011) ,  maintenance tocolysis  using nifedipine 
was ineffective in prolonging gestation or improving outcomes when compared 
with placebo or no treatment.      Twenty six trials were included and it was 
concluded that nifedipine was associated with significant reduction in risk of 
delivery within 7 days of initiation of treatment. When compared with any other 
tocolytic agent (mainly beta mimetic). 
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SUMMARY 
1. In our study, Preterm labour was common in Primigravida in age group 20 – 29 
years accounting for 77.54% compared to 22.5% between 19 and 30 years. 
2. Incidence of preterm labour in booked and unbooked cases were 80.6% and 
19.38% in nifedipine group when compared to 86.5% and 13.4% in control 
groups respectively. 
3. The success of Nifedipine as indicated by prolongation of pregnancy beyond 
48 hours was observed in 73.4% of cases compared with 57% in controls P 
value was significant (< 0.001). 
4. 78.57% of patients required 30 mg to suppress uterine contractions whereas 
21.4% required 20 mg to stop contractions. 
5. The prolongation of pregnancy more than 48 hours was found to be more in 31 
-34 weeks of gestational age in Nifedipine and control groups. 
6. Prolongation of pregnancy more than 48 hours  was seen in 53.06% in 
nifedipine group compared to 32.9% in control group 
7. Delivery occurred within 48 hours in 26.5%in nifedipine group compared to 
67.01% in control group. 
8. About 56.1% of patients in Nifedipine group had side effects which were 
reversed on discontinuation Headache ,maternal tachycardia were  the common 
side    effects 
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9. There was no maternal mortality  
10   About 11.1% and 38.46% of neonatal complications occurred in nifedipine 
success and failure groups respectively.  
11. About 34.37 % and 21.5% of neonatal complications occurred in control 
success and failure groups. 
12. Neonatal mortality was 14.28% and 22.6% among Nifedipine and control 
groups respectively 
13. Apgar score of ≤5 was seen in 4.12% and 46.1% of Nifedipine success and 
failure groups respectively. 
14 Apgar 6-7 was seen in 22.2% and 15.3% of Nifedipine success and failure 
groups. 
15. Apgar more than 7 was seen in 73.6% and 38% of Nifedipine success and 
failure groups. 
16. 84.7% Cases among Nifedipine success group had birth weight of 2 to 2.5 kg 
when compared with 56.2% in control success group. 
17. 8.3% in Nifedipine success group had birth weight > 2.5kg compared to 6.5% 
in control success group P value 0.001 statistically significant. 
18. Incidence of Respiratory Distress syndrome is 2.7 % and 15.38% in Nifedipine 
success and Failure respectively compared to 12.5% and 16.9% in control 
success and failure groups P value  
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CONCLUSION 
 
Labour inhibiting drugs may not treat the cause of preterm labour but they 
only treat the symptom that is contractions. 
  These agents make the uterus refractory to contractile stimuli for a short 
time so that the prenatal outcome is improved. In this clinical study idiopathic 
spontaneous preterm labour whose onset was at 28 to 34 weeks has responded well 
to tocolytic therapy by oral nifedipine and neonatal outcome improved and no 
maternal mortality was observed. The maternal side effects were reversed on 
discontinuation of the drug. The drug has provided the fetus of its valuable 
opportunity of being inside the mother’s womb for a period enough to make the 
lungs mature by administration of exogenous steroids. 
 However decrease in the incidence of preterm labour lies in identification of 
high risk patients, improving the socio- economic standards, better antenatal care, 
education and early detection of the onset of labour. 
 In developing countries neonatal intensive care are usually found in tertiary 
referral hospitals but not all such units have the required treatment capabilities. The 
statistically significant benefits of nifedipine in suppressing the uterine 
contractions for in utero transfer, in reducing neonatal respiratory distress 
syndrome along with its reduced maternal side effects, and its low cost makes it to 
be considered as the first line tocolytic agents in these countries  
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The success in Nifedipine and controls are 73.4% and 32.9% respectively. 
By test of proportion p value was found to be < 0.001 which is statistically 
significant. 
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Among the success groups, 73.6% belonged to Nifedipine, 56.2% belonged to control 
group having apgar >7 
P value <0.001 significant.  
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PROFORMA 
Name Age 
IP.No Unit 
Gravida 
Para Last Menstrual Period (LMP) 
Live Expected Date of Delivery (EDD) 
Abortion Corrected EDD (C.EDD) 
SES Menstrual cycle 
Occupation Height 
Residence Weight 
Booked / Unbooked (UB) 
Immunized / Not 
DOA (Date of Admission) 
Duration of Hospital stay 
DOD (Date of Discharge) 
Period of gestation 
 
Present complaints 
Lower abdominal pain 
Dull low backache 
Vaginal discharge 
Fluid leaking per vaginum 
Fever 
UTI (Urinary Tract Infection) 
URI (Upper Respiratory Tract Infection) 
Bleeding 
Obstetric history 
I. Trimester 
 
Hyperemesis 
Exanthematous fever 
Bleeding 
Radiation exposure 
Medication 
Pain abdomen 
II. Trimester 
 
Date of Quickening 
Bleeding per vaginum 
History of  PIH 
H/O GDM (Gestational Diabetes Mellitus) 
 
 
III. Trimester 
 
Bleeding per vaginum 
  UTI 
  Cervico vaginal infection 
  Coitus 
  Diabetes 
  Hypertension 
  Fever 
  Trauma 
Past obstetric history 
 
  Previous child birth 
  H/O abortion 
  H/O Preterm labour 
  H/O babies with congenital anomalies 
Past Medical History 
 
  Tuberculosis 
  Bronchial Asthma 
  STD (Sexually Transmitted Diseases) 
  Jaundice 
  Renal disease 
  Heart disease 
  Diabetes mellitus 
  Epilepsy 
General examination 
 
  Temperature (T)  Pallor   Pedal edema 
  PR BP RR  RS   CVS 
Obstetric examination 
Per Abdomen:- 
 
 Fundal height 
 Symphysio fundal height 
 Contractions 
 Presentation 
 Position 
 Liquor 
 FHR (Fetal Heart Rate) 
 Expected Fetal Weight at admission 
 Weight after birth 
 
Per Vaginal Examination (P/V) 
 
 Cervix 
Membranes 
Pelvis 
 
Investigations 
 Urine analysis 
 Urine culture sensitivity 
 Complete Blood Count 
 Blood urea, 
 Sugar 
 S. Creatinine 
 S. Electrolytes 
 ECG 
 USG Abdomen 
Nifedipine 
Time Dose Contraction T PR BP RR FHR P/V 
 
 
        
 
Side effects 
Period of tocolysis 
Mode of delivery 
Fetal Outcome 
Birth weight 
Apgar 
Neonatal complication 
 
GA
WKS (cm)Dila
tation
1 Ranjini 21 6602 PRIMI 34 B 3 30 T 2.2
2 Megala 23 3638 G2A1 30 B 3 20 N,V 1.7
3 Gowsalya 18 6610 PRIMI 34 B 3 30 Ft 2.3
4 Nithya 21 6638 PRIMI 34 B 3 30 H 2.2
5 Priyadarshni 28 6820 G3P1L1A1 32 B 3 30 T 2
6 Ponni 20 6230 PRIMI 30 B 2 20 N,V 1.6
7 Nadiya 27 6719 G2P1L1 34 B 3 30 H 2.3
8 Sathya 26 6002 G2A1 34 UB 3 30 2.2
9 Pushpa 22 6125 PRIMI 30 UB 3 20 N,V 1.5
10 Sumathi 28 6560 G2P1L1 34 UB 3 30 T 2.2
11 Selvi 31 6647 G3P1L1A1 34 UB 3 30 2.1
12 Divya 18 6503 PRIMI 34 B 3 30 2.3
13 Vanitha 21 6799 PRIMI 28 B 3 20 T 1.6
14 Devi 23 6905 G3P2L1A1 30 B 3 30 H 1.7
15 Kavitha 26 6820 G2P1L1 34 B 2 30 H 2.4
16 Panchavarnam 21 6250 PRIMI 34 UB 3 30 2.2
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o
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17 Ramjan Begum 19 6325 PRIMI 34 B 2 30 H 2.5
18 Saraswathy 27 6973 G2P1L1 32 B 3 20 2.1
19 Esther 32 7010 G4P2L2A1 30 UB 3 30 H 1.5
20 Rani 21 7094 G3P2L2 32 B 3 20 T 1.9
21 Babitha 29 7118 G3P1L1A1 34 UB 3 30 2.3
22 Sangeetha 22 6561 G2A1 30 B 3 30 2
23 Hemalatha 18 7091 PRIMI 34 B 3 20 2.2
24 Yamuna 23 7729 PRIMI 34 B 3 30 2.3
25 Jeeva 28 7635 G2P1L1 34 UB 3 30 2.1
26 Kavitha 27 7780 PRIMI 28 B 2 30 H 1.6
27 Girija 19 10203 PRIMI 32 B 3 20 N,V 2
28 Parvathy 31 8967 G4P3L1 34 UB 3 30 T 2.2
29 Thirupurasundari 27 10250 PRIMI 34 B 3 30 2
30 Deepika 22 10295 G2P1L1 30 UB 3 30 T 2
31 Pavithra 26 10172 PRIMI 34 B 3 30 Ft 2.3
32 Santhini 24 10332 G2P1L1 30 B 3 30 1.5
33 Fathima 28 10312 G2P1L1 32 UB 3 20 ↓BP 2
34 Megala 18 10373 PRIMI 34 B 2 30 2.4
35 Gomathy 22 10413 PRIMI 28 B 3 30 T 1.6
36 Keerthana 26 10466 PRIMI 34 B 3 30 2.2
37 Ambiga 30 10362 G3P2L2 32 B 2 20 H 1.8
2+
2+
3+
3+
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38 Nandhini 23 10405 PRIMI 34 B 3 30 T 2.2
39 Lakshmi 27 10501 PRIMI 34 B 2 30 T 2.3
40 Revathy 19 10521 G2P1L1 32 UB 3 30 N,V 1.8
41 Subalakshmi 28 10581 G2P1L1 34 B 3 30 2.2
42 Bhavani 23 10598 PRIMI 34 B 3 20 N,V 2.3
43 Malathy 26 10698 PRIMI 30 B 3 30 T 1.5
44 Thenmozhi 22 10840 G3P1L1A1 30 B 3 30 Ft 1.2
45 Mahalakshmi 28 10851 PRIMI 34 B 3 30 T 2.2
46 Nandini 17 10791 PRIMI 32 UB 2 30 N,V 1.9
47 Dhanalakshmi 27 10914 PRIMI 32 B 3 20 T 1.8
48 Norrjahan 21 10786 PRIMI 32 B 3 30 1.7
49 Devi 31 10998 G2P1L1 34 B 3 30 2.2
50 Punitha 26 11015 PRIMI 30 B 3 30 1.6
51 Rekha 29 11017 G2P1L1 34 B 3 20 2.4
52 Rashida 23 11071 PRIMI 34 B 3 30 Ft 2.2
53 Shakila 27 11084 PRIMI 34 UB 2 30 ↓BP 2.4
54 Savithiri 21 11138 G2A1 30 B 3 20 N,V 1.6
55 Divya 27 11150 PRIMI 34 B 3 30 2
56 Vaitheeswari 19 11207 PRIMI 34 B 3 30 T 2.3
57 Kala 25 11193 G2P1L1 28 UB 3 30 1.6
58 Sindu 26 11076 PRIMI 34 B 3 20 2.3
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59 Malathy 22 11269 PRIMI 30 B 3 30 H 1.5
60 Maheswari 28 11080 G2P1L1 34 UB 3 30 2.2
61 Taj Begum 21 11243 PRIMI 34 B 3 30 FF 2.3
62 Kalaiarasi 27 11253 G2P1L1 30 UB 3 30 ↓BP 1.7
63 Egavalli 19 11196 PRIMI 32 B 3 30 T 1.7
64 Reena 23 11247 PRIMI 34 B 3 30 H 2.2
65 Rani 31 11375 PRIMI 28 B 3 30 1.5
66 Sagayamary 24 2208 G2P1L1 32 B 2 30 H 2
67 Nandini 21 12238 PRIMI 34 B 3 30 2.4
68 Shalini 24 12235 G3P2L2 32 UB 3 20 H 1.8
69 Mohana 21 12248 PRIMI 30 B 3 30 N,V 2
70 Hamsa 22 12331 PRIMI 34 B 2 30 H 2
71 Rajjya 27 12398 PRIMI 34 B 3 30 2.2
72 Lavanya 25 12301 PRIMI 34 B 3 30 H 2.3
73 Shanthi 20 12488 PRIMI 30 B 3 30 1.6
74 Chitra 25 12225 PRIMI 34 B 2 30 2
75 Yasoda 24 12599 PRIMI 32 B 3 20 ↓BP 1.9
76 Vasanthi 18 12613 PRIMI 30 B 3 30 1.6
77 Subhasini 25 12236 PRIMI 34 B 3 30 N,V 2.2
78 Bhavani 25 12593 PRIMI 32 B 2 30 H 2
79 Hemalatha 21 12616 G2A1 34 UB 3 30 2.4
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80 Radhika 26 12665 G2A1 34 B 3 20 2.5
81 Barkath 23 8874 PRIMI 34 B 3 30 FF 2.4
82 Pavithra 28 8887 G2P1L1 32 B 3 30 1.8
83 Amala 26 8984 PRIMI 34 B 3 30 2.2
84 Kalaivani 32 8934 G2P1L1 30 B 3 20 H 1.5
85 Sasikala 26 8881 G2P1L1 28 B 3 30 1.2
86 Menaka 21 8974 PRIMI 34 B 3 30 FF 2.2
87 Ammu 29 9019 G2P1L1 32 UB 3 20 H 2.1
88 Ilamathy 23 9077 PRIMI 30 B 3 30 1.4
89 Divya 20 9113 PRIMI 34 B 3 30 2.3
90 Gomahy 27 9166 G2P1L1 32 UB 2 30 1.8
91 Bhavani 27 9174 PRIMI 34 B 3 30 H 2.4
92 Devi 25 9051 PRIMI 32 B 3 30 ↓BP 2.1
93 Abirami 24 9136 PRIMI 30 B 3 30 1.5
94 Kalaichelvi 26 9225 PRIMI 34 B 3 30 2.3
95 Poongodi 29 9025 PRIMI 34 B 3 20 ↓BP 2.4
96 Usha 25 9189 PRIMI 30 B 3 30 H 1.9
97 Anuradha 26 9409 PRIMI 34 B 3 30 2.2
98 Prema 31 9210 G2P1L1 30 UB 3 30 H 1.6
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B/UB (cm)Dila
tation
1 Priya 25 6577 PRIMI B 30 3 F 1.60
2 Gayathri 27 6605 PRIMI B 34 3 F 2.30
3 Sasi 21 3639 G3P1L1A1 B 34 3 S 2.40
4 Banupriya 26 6613 PRIMI B 32 3 F 1.90
5 Saranya 23 6559 PRIMI B 34 3 F 2.30
6 Jerina Begum 26 6661 PRIMI B 30 3 F 1.70
7 Ambiga 24 6682 PRIMI B 34 3 S 2.40
8 Shantha 23 9842 G2P1L1 B 34 3 S 2.40
9 Jailani 22 6742 G2P1L0 B 28 3 F 1.40
10 Amulu 27 6625 PRIMI B 34 3 S 2.50
11 Aishwarya 26 9804 G2P1L1 B 30 3 F 1.70
12 Maheswari 28 6812 G2P1L1 UB 30 3 F 1.80
13 Radika 24 6771 PRIMI B 34 3 V A F 2.30 8
14 Sasikala 23 6778 PRIMI B 34 3 F 2.25
15 Rajeshwari 28 6875 G2P1L1 B 32 3 F 1.90V A 5 2
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CONTROLS 
S.No Name Age IP.No OBST CODE GA wks
M
o
d
e
 
o
f
 
D
e
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e
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y
16 Jhansi 22 6865 PRIMI B 30 3 F 1.70
17 Rekha 23 6925 PRIMI UB 32 3 F 1.90
18 Priya 26 6205 PRIMI B 30 3 F 1.80
19 Mary 25 7054 G2P1L1 B 32 3 F 1.90
20 Sangeeta 24 6561 G2A1 UB 34 3 S 2.40
21 Selvi 23 7015 PRIMI B 30 3 F 1.70
22 Devi 27 7241 G3P1L1A1 B 32 3 F 2.00
23 Mary 29 7054 G2P1L1 B 33 3 F 2.10
24 Saraswathy 31 6973 PRIMI B 34 3 S 2.40
25 Esther 26 7010 PRIMI UB 28 3 F 1.50
26 Tamilselvi 28 7151 G3P1L1A1 B 30 3 F 1.80
27 Gomathi 24 7736 PRIMI B 34 2 S 2.40
28 Kowsiya 23 7795 PRIMI B 34 3 F 2.30
29 Gunasundari 31 10246 G2P1L1 B 30 3 F 1.70
30 Monika 26 10244 PRIMI B 34 3 S 2.40
31 Saraswathy 28 10194 G2P1L1 UB 32 3 F 2.10
32 Bhavani 24 10346 PRIMI B 34 3 S 2.40
33 Elakiya 27 10343 G2P1L1 B 30 3 F 1.70
34 Anjali 19 10357 G2P1L1 UB 32 3 F 2.00
35 Gunasundari 28 10355 G2P1L1 B 34 3 S 2.30V B 6 3
V A 5 1+
V A 6
V A 6
V B 8 3
V A 5 2+
V B 6
V B 8 2
V A 6
V A 5 1+
V A 8 2
V A 6
V B 6 2
V A 5 2
V A 6
V A 5
V B 7
V A 6
V A 5
V A 5 2
36 Jyothy 23 10409 PRIMI B 30 3 F 1.60
37 Nagavalli 26 10437 G2A1 B 34 3 S 2.40
38 Jerina 22 10370 PRIMI B 34 3 F 2.30
39 Megala 19 10330 PRIMI B 30 3 F 1.70
40 Priya 27 10267 G2P1L1 B 34 3 S 2.30
41 Soniya 26 10530 PRIMI UB 33 3 F 2.00
42 Amudavalli 21 10607 PRIMI B 32 3 F 2.00
43 Amudha 28 10147 PRIMI B 30 3 F 1.60
44 Bhuvaneshwari 23 10738 PRIMI B 32 3 S 1.90
45 Latha 27 10845 PRIMI B 30 3 F 1.70
46 Selvi 22 10799 PRIMI UB 34 3 S 2.30
47 Seetha 24 10811 PRIMI B 32 3 S 1.90
48 Priya 17 10928 PRIMI B 30 3 F 1.60
49 Devi 18 10932 PRIMI B 32 3 S 2.10
50 Karpagam 26 10975 G2P1L1 B 30 3 S 1.80
51 Deepa 28 10998 G2P1L1 B 34 3 S 2.30
52 Jennifer 23 10956 PRIMI B 30 3 F 1.90
53 Anitha 19 11039 PRIMI B 34 3 S 2.40
54 Ambika 23 11117 PRIMI B 34 3 S 2.50
55 Kanchana 19 11134 PRIMI B 28 3 S 1.50V B 5
V B 8
V B 7
V B 8
V A 5
V B 5 3+
V B 5 3+
V B 5
V A 5
V A 4
V B 7
V A 5
V B 5 3+
V A 7
V A 7
V A 5
V B 4 3+
V B 7
V A 5
V A 5
56 Malar 27 112256 G2P1L1 B 30 3 F 1.60
57 Rosy 23 11106 PRIMI UB 34 3 S 2.30
58 Vasanthi 28 11266 G2P1L1 B 34 3 S 2.40
59 Sheela 32 11236 G2P1L1 B 34 3 S 2.30
60 Shakeena 21 11234 PRIMI B 30 3 F 1.90
61 Pandipriya 26 11260 G2P1L1 B 32 3 F 2.00
62 Sakira 18 11361 PRIMI B 34 3 S 2.30
63 Mini 19 11385 G2P1L1A1 UB 32 3 F 1.90
64 Bhuvaneshwari 27 11393 G2P1L1 B 34 3 S 2.30
65 Suganya 19 12186 PRIMI B 32 3 F 2.00
66 Barathi 19 12239 PRIMI B 34 3 F 2.20
67 Sareen 27 12082 PRIMI UB 32 3 F 2.00
68 Bakya 22 12195 G2A1 B 32 3 F 1.90
69 Suganya 26 12320 G2A1 B 30 3 F 1.60
70 Priya 18 12265 G2P1L1 UB 34 3 F 1.90
71 Mariammal 24 12389 G2P1L1 B 30 3 F 1.60
72 Aishwarya 18 12453 PRIMI UB 32 3 F 1.90
73 Vedavalli 31 12465 G2P1L1 B 30 3 F 1.60
74 Sujitha 22 12522 PRIMI B 34 3 S 2.40
75 Indumathy 26 12552 G3P1L1A1 B 34 3 S 2.30V B 7
V A 5
V B 8
V A 4
V A 5
V A 5 2+
V A 6
V A 7 2+
V A 5
V A 5
V A 5
V A 6
V B 8 4
V A 8
V B 5
V B 7
V A 7
V B 7
V B 8
V A 5
76 Lakshmi 18 12612 PRIMI B 34 2 S 2.30
77 Nalini 24 12474 PRIMI B 32 2 F 2.00
78 Gayathri 19 15573 G2P1L1 B 34 3 S 2.20
79 Betisda 22 12672 PRIMI B 32 3 F 1.90
80 Kavitha 24 8774 PRIMI B 30 2 F 1.70
81 Selvi 30 8726 G3P1L1A1 B 34 3 S 2.40
82 Madhuri 21 8919 G2A1 B 30 3 F 1.70
83 Solaiyammal 23 8931 PRIMI B 34 3 S 2.20
84 Mohana 31 8984 G4P1L1A2 B 28 2 F 1.40
85 Amuda 21 8974 PRIMI B 32 3 F 2.00
86 Anbu 22 8118 PRIMI B 34 3 F 2.30
87 Krithika 24 9070 G2P1LI B 32 3 F 2.00
88 Priyanka 17 9095 PRIMI B 30 3 F 2.00
89 Sandhya 24 9044 PRIMI B 32 3 F 2.10
90 Revathy 21 9165 PRIMI B 33 3 F 2.20
91 Elakiya 18 9178 G2P1L1 B 32 3 F 2.30
92 Maheswari 32 9202 G2P1L1 B 30 3 S 1.60
93 Archana 23 9179 G2P1L1 B 32 3 F 2.00
94 Rumeena 25 9047 PRIMI B 34 3 F 2.20
95 Sridevi 23 9236 PRIMI B 32 3 F 2.10V A 5 3+
V A 5
V A 7
V A 8
V B 5
V A 7
V A 5 3+
V A 7 3+
V A 7
V A 8 3
V A 8
V B 7
V A 5 4+
V B 7
V A 4 4+
V A 8
V A 5 0
V A 5 +
V B 8
V B 8
96 Lakshmi 31 9233 G2P1L1 B 30 3 F 1.60
97 Sudha 22 9063 PRIMI B 32 3 F 1.90
G - Gravida P - Para L - Life A - Abortion GA - Gestational Age
Wt - Weight B - Booked UB - Un booked  S - Success F - Failure V - Vaginal Delivery
HR - Heart rate T - Tachycardia          H - Hypotension FF - Facial Flushing
N,V - Nausea Vomiting           +  Neonatal Mortality 1 - Birth asphyxia 2 respiratory Distress 
Syndrome
3 -  Septicemia        4 - Intra ventricular Haemorrhage       
A - Delivery less than 48 hours           B - Delivery at 48 hours C - Up to 72 Hours
D - Up to 5 days               E - Up to 1 Week
V A 5
V A 5
